- Home
- SGN vs TCRT Comparison
SGN vs TCRT Comparison
Compare SGN & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- TCRT
- Stock Information
- Founded
- SGN 2019
- TCRT 1998
- Country
- SGN United States
- TCRT United States
- Employees
- SGN N/A
- TCRT N/A
- Industry
- SGN
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- TCRT Health Care
- Exchange
- SGN Nasdaq
- TCRT Nasdaq
- Market Cap
- SGN 3.8M
- TCRT 3.8M
- IPO Year
- SGN 2023
- TCRT N/A
- Fundamental
- Price
- SGN $1.51
- TCRT $2.81
- Analyst Decision
- SGN
- TCRT
- Analyst Count
- SGN 0
- TCRT 0
- Target Price
- SGN N/A
- TCRT N/A
- AVG Volume (30 Days)
- SGN 7.0M
- TCRT 59.9K
- Earning Date
- SGN 08-18-2025
- TCRT 08-13-2025
- Dividend Yield
- SGN N/A
- TCRT N/A
- EPS Growth
- SGN N/A
- TCRT N/A
- EPS
- SGN N/A
- TCRT N/A
- Revenue
- SGN $529,282.00
- TCRT $11,000.00
- Revenue This Year
- SGN N/A
- TCRT $5,680,500.00
- Revenue Next Year
- SGN N/A
- TCRT N/A
- P/E Ratio
- SGN N/A
- TCRT N/A
- Revenue Growth
- SGN 8.42
- TCRT 83.33
- 52 Week Low
- SGN $0.44
- TCRT $1.31
- 52 Week High
- SGN $36.70
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- SGN 48.89
- TCRT 32.13
- Support Level
- SGN $1.83
- TCRT $2.82
- Resistance Level
- SGN $2.27
- TCRT $3.22
- Average True Range (ATR)
- SGN 0.35
- TCRT 0.50
- MACD
- SGN -0.05
- TCRT -0.22
- Stochastic Oscillator
- SGN 21.93
- TCRT 8.32
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.